Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GID4 | Q8IVV7 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13444088 | 1.00 | GID4 (0.72) | GID4MAPK1MAPK14ALDH1A1HAO1 | |
| SCHEMBL28596328 | 0.84 | GID4 (0.59) | GID4MAPK1MAPK14KDM1AMAOA | |
| SCHEMBL20863607 | 0.84 | GID4 (1.00) | GID4MAPK1MAPK14ALDH1A1KMT2A | |
| SCHEMBL6306064 | 0.82 | GID4 (0.68) | GID4MAPK1MAPK14KDM1AMAOA | |
| SCHEMBL395087 | 0.81 | GID4 (0.62) | GID4MAPK1MAPK14ALDH1A1HAO1 | |
| SCHEMBL29842306 | 0.81 | GID4 (0.62) | GID4MAPK1MAPK14ALDH1A1HAO1 | |
| SCHEMBL20863599 | 0.79 | HAO1 (0.53) | GID4MAPK1MAPK14HAO1 | |
| SCHEMBL7059074 | 0.79 | HAO1 (0.57) | GID4MAPK1MAPK14ALDH1A1HAO1 | |
| SCHEMBL20874477 | 0.79 | GID4 (0.56) | GID4MAPK1MAPK14ALDH1A1HAO1 | |
| SCHEMBL20863578 | 0.79 | HAO1 (0.53) | GID4MAPK1MAPK14ALDH1A1HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2020-08-13 | — | — | US | disclosed |
| WO-2019063955-A1 | AGENTS INHIBITING TCTP PROTEIN FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | UNIVERSITE PARIS-SUD (FR) | 2019-04-04 | — | — | WO | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | PHARMACIA | 2008-03-13 | — | — | US | disclosed |
| US-4556676-A | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-12-03 | — | — | US | disclosed |
| US-4536518-A | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine | PFIZER INC. (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0030081-B1 | ANTIDEPRESSANT DERIVATIVES OF CIS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0028901-B1 | ANTIDEPRESSANT DERIVATIVES OF TRANS-4-PHENYL-1,2,3,4-TETRAHYDRO-1-NAPHTHALENAMINE AND PHARMACEUTICAL COMPOSITIONS THEREOF | PFIZER INC. (US) | 1983-03-02 | — | — | EP | disclosed |
| EP-0030081-A1 | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-06-10 | — | — | EP | disclosed |
| EP-0028901-A1 | Antidepressant derivatives of trans-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine and pharmaceutical compositions thereof | PFIZER INC. (US) | 1981-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064716-A1 | Alpha v beta 3 and/or alpha v beta 5 integrin inhibitors; osteoporosis, retinopathy, tumor metastasis and angiogenesis; decreased side effects, improved potency; 3-(2-(3-[2-(5,6,7,8- Tetrahydro-1,8-naphthyridin-2-yl)ethoxy]benzyl}-phenyl)propionic acid | ITGA5, ITGAV, ITGB5 | GID4 918/4885MAPK1 1307/4885MAPK14 2940/4885 |
| US-20200253996-A1 | TCTP INHIBITING AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES, INFECTIOUS DISEASES, ALLERGIES, INFLAMMATIONS AND/OR ASTHMA | NR3C1, TSLP, FPR3 | GID4 2937/4885MAPK1 1286/4885MAPK14 94/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | GID4 3096/4885MAPK1 4781/4885MAPK14 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.